Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival
Author:
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,Oncology
Link
http://academic.oup.com/jnci/article-pdf/107/11/djv239/17986010/djv239.pdf
Reference15 articles.
1. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2. Individual patient data analysis to assess modifications to the RECIST criteria
3. Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non Small-Cell Lung Cancer
4. Designing exploratory cancer trials using change in tumour size as primary endpoint
5. Evaluation of Tumor-Size Response Metrics to Predict Overall Survival in Western and Chinese Patients With First-Line Metastatic Colorectal Cancer
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Circulating tumor cell abundance in head and neck squamous cell carcinoma decreases with successful chemoradiation and cetuximab treatment;Cancer Letters;2023-05
2. Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group – ESOI Joint Paper;Frontiers in Oncology;2022-01-10
3. Modeling tumor measurement data to predict overall survival (OS) in cancer clinical trials;Contemporary Clinical Trials Communications;2021-09
4. Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer;PLOS ONE;2021-07-01
5. A Primer on RECIST 1.1 for Oncologic Imaging in Clinical Drug Trials;Radiology: Imaging Cancer;2021-05-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3